Table 1 Tumor cytoplasmic CSE1L expression and clinical parameters in CRC
| Â | Cytoplasmic CSE1L | Total | P | |
|---|---|---|---|---|
| Â | Low (1+) | High (2+ or 3+) | Â | Â |
Sex | Â | Â | Â | Â |
female | 26 (50)# | 26 (50) | 52 | 0.884 |
male | 37 (48.7) | 39 (51.3) | 76 | Â |
Grade | Â | Â | Â | Â |
well | 2 (50) | 2 (50) | 4 | 0.138 |
moderate | 55 (47) | 62 (53) | 117 | Â |
poor | 6 (85.7) | 1 (14.3) | 7 | Â |
T status | Â | Â | Â | Â |
T1+T2 | 16 (76.2) | 5 (23.8) | 21 | 0.007* |
T3+T4 | 47 (43.9) | 60 (56.1) | 107 | Â |
Lymph node metastasis | Â | Â | Â | Â |
no | 42 (56) | 33 (44) | 75 | 0.068 |
yes | 21 (39.6) | 32 (60.4) | 53 | Â |
Distant metastasis | Â | Â | Â | Â |
no | 56 (50.5) | 55 (49.5) | 111 | 0.476 |
yes | 7 (41.2) | 10 (58.8) | 17 | Â |
Stage | Â | Â | Â | Â |
I | 16 (80) | 4 (20) | 20 | 0.018* |
II | 22 (45.8) | 26 (54.2) | 48 | Â |
III | 20 (45.5) | 24 (54.5) | 44 | Â |
IV | 5 (31.3) | 11 (68.8) | 16 | Â |
Stage | Â | Â | Â | Â |
I/ II | 38 (55.9) | 30 (44.1) | 68 | 0.108 |
III/IV | 25 (41.7) | 35 (58.3) | 60 | Â |
Overall survival | Â | Â | Â | Â |
≤5 y | 33 (44.6) | 41 (55.4) | 74 | 0.221 |
≥5 y | 30 (55.6) | 24 (44.4) | 54 |  |